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Supplementation of krill oil with high
phospholipid content increases sum of EPA
and DHA in erythrocytes compared with
low phospholipid krill oil
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Abstract
Background: Bioavailability of krill oil has been suggested to be higher than fish oil as much of the EPA and DHA
in krill oil are bound to phospholipids (PL). Hence, PL content in krill oil might play an important role in incorporation
of n-3 PUFA into the RBC, conferring properties that render it effective in reducing cardiovascular disease (CVD) risk.
The objective of the present trial was to test the effect of different amounts of PL in krill oil on the bioavailability of EPA
and DHA, assessed as the rate of increase of n-3 PUFA in plasma and RBC, in healthy volunteers.
Methods and design: In a semi randomized crossover single blind design study, 20 healthy participants consumed
various oils consisting of 1.5 g/day of low PL krill oil (LPL), 3 g/day of high PL krill oil (HPL) or 3 g/day of a placebo, corn
oil, for 4 weeks each separated by 8 week washout periods. Both LPL and HPL delivered 600 mg of total n-3 PUFA/day
along with 600 and 1200 mg/day of PL, respectively.
Results: Changes in plasma EPA, DPA, DHA, total n-3 PUFA, n-6:n-3 ratio and EPA + DHA concentrations between LPL
and HPL krill oil supplementations were observed to be similar. Intake of both forms of krill oils increased the RBC level
of EPA (p < 0.001) along with reduced n-6 PUFA (LPL: p < 0.001: HPL: p = 0.007) compared to control. HPL consumption
increased (p < 0.001) RBC concentrations of EPA, DPA, total and n-3 PUFA compared with LPL. Furthermore, although
LPL did not alter RBC n-6:n-3 ratio or the sum of EPA and DHA compared to control, HPL intake decreased (p < 0.001)
n-6:n-3 ratio relative to control with elevated (p < 0.001) sum of EPA and DHA compared to control as well as to LPL
krill oil consumption. HPL krill oil intake elevated (p < 0.005) plasma total and LDL cholesterol concentrations compared
to control, while LPL krill oil did not alter total and LDL cholesterol, relative to control.
Conclusions: The results indicate that krill oil with higher PL levels could lead to enhanced bioavailability of n-3 PUFA
compared to krill oil with lower PL levels.
Trial registration: Clinicaltrials.gov# NCT01323036.
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Introduction
Marine n-3 polyunsaturated fatty acids (PUFA), including
EPA and DHA, have been demonstrated to play beneficial
roles in prevention of cardiovascular disease (CVD) [1, 2].
In addition to decreasing circulating lipid concentrations
[3], n-3 PUFA have been found to reduce systolic blood
pressure, inflammatory process and platelet aggregation as
well as prevent arrhythmias [1, 4]. Consumption of n-3
PUFA including EPA and DHA occurs mainly through
intake of oily fish or through supplements where the n-3
PUFA are usually esterified to glycerol of triglycerides
(TG). However, other marine sources, such as krill oil, in
which the n-3 PUFA are esterified to glycerol of phospho-
lipids (PL), could also be used as source for n-3 PUFA.
Consumption of n-3 PUFA esterified to PLs has been
shown to exert a wide range of health benefits such as
plasma lipid reduction [5], enhanced bioavailability of EPA
and DHA [6–8] as well as anti-inflammatory [9] and
antioxidant activity [10].
Krill oil has drawn a great interest as the PL-bound
fatty acids are more efficiently absorbed and incorpo-
rated into cell membranes. Several animal and human
studies have shown krill oil to be more efficient than fish
oil in enhancing plasma and RBC n-3 PUFA and im-
proving risk markers for CVD [5–8, 11, 12]. Studies have
shown enhanced absorption of n-3 fatty acids into target
organs such as heart, brain and liver when attached to
PL compared to TG [9, 13, 14]. Benefits of krill over fish
oil might be due to the structural differences between
the two oils where the n-3 PUFA in krill and fish oil are
esterified with PL and TG, respectively. The primary PL
in krill oil is phosphatidylcholine (PC), and approxi-
mately 60–70 % of the omega-3 fatty acids in krill oil are
bound to PLs.
Association between PL and long-chain n-3 PUFA
facilitates the transfer of fatty acid molecules through
the intestinal wall, increasing bioavailability and thereby
improving the n-3:n-6 PUFA ratio [15]. As PL esterified
n-3 PUFA are absorbed efficiently, amounts of PL
present in the krill oil could play an important role in
absorption, bioavailability and incorporation into differ-
ent cellular compartments.
The objective of the present trial was to assess the bio-
availability of krill oil consisting low PL content (LPL)
compared to krill oil with high PL content (HPL), with
similar n-3 PUFA content, and a placebo. The specific ob-
jective included assessment and comparison of fatty acid
composition in plasma as well as incorporation into red
blood cells of volunteers at baseline and following 4 weeks
of intervention with each of the oils, each separated by an
8 week washout period. Another objective was to measure
lipid profiles including total cholesterol, HDL, LDL, and
TG levels following 4 weeks consumption of LPL or HPL
krill oil.
Results
Twenty out of 24 participants who completed the first
three phases continued and completed the study for the
4th phase with LPL treatment. Vital signs including body
weight, systolic and diastolic blood pressure and heart
rate were within normal ranges (Table 1). Physical
examination by the physician revealed that none of the
participants had any health problems or concerns
known to affect study outcomes. The study physician
recorded and compared the health status of participants
at each visit. None of the participants during the study
showed major changes in their health status related to
the trial.
A weekly telephone questionnaire was completed by
the study coordinator to monitor compliance. Questions
included capsule intake, fish or sea food intake, adverse
events and concomitant medication use. No adverse or
serious adverse events related to the treatments were
reported during the period of the study. During the
study one participant experienced a minor stomach ulcer
which, with treatment by a physician, was resolved in
two weeks. The event occurred only during the washout
period and was deemed not related to the study by the
study physician. None of the participants consumed any
concomitant medications or supplements that are known
to affect study outcomes. All participants followed the
guidelines not to eat more than one serving per month of
fish or sea food. None of the participants exceeded the
limit of fish or sea food consumption during intervention
or washout periods. No differences with the gastrointes-
tinal responses were observed between the LPL and HPL
krill oil and placebo consumptions.
Participants consumed the study capsules regularly
according to instructions provided. According to the
self-reported capsule consumption checklist each partici-
pant completed, participants showed high compliance
with capsule consumption. The compliance ratings for
capsule consumption during LPL krill oil was 94.6 %
compared to 95.8 % for HPL krill oil and 97.4 % for
placebo interventions.
The safety with consumption of LPL krill was deter-
mined by measuring blood parameters including WBC,
RBC, hematocrit, hemoglobin, and platelet count, neu-
trophils, lymphocytes, monocytes, eosinophils, basophils,
MCV, MCH and MCHC values. No significant differ-
ences were found in the above parameters between
consumption of placebo or LPL or HPL krill oil (Data
not shown).
Anthropometric measures were performed at the be-
ginning and end of each phase. At baseline, 16 partici-
pants were of BMI < 25 and 8 participants had a BMI
between 25 and 28. No significant changes were observed
in any of the anthropometric measures between different
treatments phases except for a decrease (p = 0.033) in
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body weight following consumption of LPL, relative to
HPL (Table 1).
Consumption of HPL krill oil elevated the plasma
concentrations of EPA (p < 0.001), DPA (p = 0.015),
DHA (p < 0.001), n-3 PUFA (p < 0.001) and EPA + DHA
(p < 0.001) relative to control. No significant change in
total PUFA was observed compared to control (Table 2).
Similarly, LPL krill oil increased (p < 0.001) the plasma
concentrations of EPA, DPA, DHA, n-3 PUFA and EPA
+ DHA. Both LPL and HPL krill oils reduced n-6:n-3
ratio (p < 0.001), while only LPL krill oil reduced n-6
PUFA (p = 0.031) compared to control.
Comparing the change between HPL and LPL showed
no differences in plasma EPA, DPA, DHA, total PUFA,
total n-3, EPA + DHA and n-6:n-3 ratio following
consumption of the two oils (Table 2). However, LPL
krill oil intake reduced the SFA (p = 0.035) and n-6
PUFA (p = 0.040) and increased MUFA (p = 0.037) in
plasma compared with HPL krill oil (Table 2).
Intake of HPL krill oil significantly increased RBC
concentrations of EPA (p < 0.001), DHA (p = 0.017),
EPA + DHA (the omega-3 index, p < 0.001) and n-3
PUFA (p < 0.001) compared to control. HPL krill oil
consumption decreased n-6 PUFA (p = 0.007) and n-
6:n-3 ratio (p = 0.021), with no significant difference
in DPA, and total PUFA levels, compared to control
(Table 3).
LPL krill oil supplementation increased EPA concentra-
tion in the RBC compared to control (p < 0.001). Interest-
ingly, LPL krill oil consumption failed to change the RBC
concentrations of DPA, DHA, n-6:n-3 ratio and EPA +
DHA compared to control. LPL krill oil reduced total
PUFA (p < 0.025) and total n-6 PUFA (p < 0.001) con-
centrations in RBC compared to control. Importantly,
consumption of HPL krill oil led to elevations in RBC
concentrations of EPA (p < 0.001), DPA (p < 0.040), total
PUFA (p < 0.030), total n-3 PUFA (p < 0.040) and EPA +
DHA (p < 0.020), compared to LPL (Table 3).
No significant changes were found in serum lipid con-
centrations and ratio between total and HDL cholesterol
of participants during the ingestion of LPL krill compared
to HPL krill oil (Table 4). However, HPL krill oil supple-
mentation elevated serum total (p = 0.024) and LDL chol-
esterol concentrations (p < 0.001) compared to control.
Table 1 Anthropometric measures of participants during HPL and LPL krill and control oil interventions
Parameter Treatment Baseline Endpoint Change (Difference)
Body Weight (Kg) HPL Krill oil 67.53 ± 2.75 67.96 ± 2.63 0.43 ± 0.37
LPL krill oil 67.99 ± 2.77 67.74 ± 2.73 −0.25 ± 0.22a
Control 67.56 ± 2.46 67.73 ± 2.44 0.18 ± 0.22
BMI (kg/m2) HPL Krill oil 23.62 ± 0.68 23.75 ± 0.63 0.13 ± 0.15
LPL krill oil 23.79 ± 0.71 23.69 ± 0.71 −0.10 ± 0.08
Control 23.61 ± 0.63 23.67 ± 0.62 0.06 ± 0.09
Waist (cm) HPL Krill oil 77.95 ± 1.98 78.20 ± 1.93 0.25 ± 0.27
LPL krill oil 78.25 ± 2.03 77.81 ± 2.05 −0.43 ± 0.37
Control 78.05 ± 1.80 78.14 ± 1.78 0.09 ± 0.15
Hip (cm) HPL Krill oil 92.04 ± 1.19 92.45 ± 1.14 0.41 ± 0.34
LPL krill oil 92.69 ± 1.22 92.92 ± 1.20 0.23 ± 0.28
Control 92.70 ± 1.10 92.71 ± 1.07 0.01 ± 0.12
Waist/Hip ratio HPL Krill oil 0.85 ± 0.02 0.84 ± 0.02 0.00 ± 0.00
LPL krill oil 0.84 ± 0.02 0.84 ± 0.02 −0.01 ± 0.00
Control 0.84 ± 0.02 0.84 ± 0.01 0.00 ± 0.00
Systolic BP (mmHg) HPL Krill oil 106.80 ± 2.63 108.14 ± 2.00a 1.35 ± 1.39
LPL krill oil 106.35 ± 2.45 103.97 ± 2.73 −2.38 ± 1.56
Control 107.99 ± 2.13 105.89 ± 2.36 −2.11 ± 1.15
Diastolic BP (mmHg) HPL Krill oil 71.45 ± 1.69 72.53 ± 1.32 1.09 ± 0.88
LPL krill oil 71.17 ± 1.96 70.5 ± 1.86 −0.67 ± 1.34
Control 72.26 ± 1.68 71.05 ± 1.84 −1.21 ± 1.05
Heart rate (Beats/min) HPL Krill oil 71.35 ± 2.43 70.25 ± 1.72 −1.10 ± 2.07
LPL krill oil 73.25 ± 2.23 69.1 ± 1.74 −4.15 ± 1.70
Control 71.55 ± 1.66 71.80 ± 1.65 0.25 ± 1.09
Values are expressed as Mean ± SEM. n = 20. adenotes significance compared with LPL krill oil intervention
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Discussion
In the present study, consumption of HPL and LPL krill
oil exhibited similar effects on plasma fatty acids profile
but different actions on RBC fatty acid concentrations.
Results suggest that the absorption of omega-3 fatty
acids in plasma is less affected by the amount of PLs, as
the level of EPA, DHA, DPA and total n-3 PUFA, while
increasing compared to control, did not consistently
change according to PL levels (Table 2). Nonetheless, in-
corporation of absorbed n-3 PUFAs into the membranes
of RBC appears to depend on the amount of PL in the
test product used. Results show that levels of EPA, DPA,
total n-3 PUFA and EPA + DHA in RBC were increased
following HPL krill oil consumption compared to LPL
krill oil (Table 3). The difference between absorption of
omega-3 fatty acids into plasma and into RBC may be
significant relating to the fate of these fatty acids. While
plasma levels of EPA and DHA are considered a marker
of short term absorption, easily affected by levels of
omega-3 in the supplement, their levels in RBC are
markers of long term absorption as well as of tissue
absorption of these fatty acids [16, 17]. The exact mech-
anism by which PL influence the incorporation of n-3
PUFA into RBC is not completely understood and needs
to be further investigated.
PLs are well recognised for their role in structure and
function of cell membranes as well as formation of lipo-
protein, and transportation and delivery of lipids to vari-
ous tissues through the blood [18]. PLs are amphiphilic
in nature and hence possess emulsifying properties. PLs
Table 2 Plasma fatty acids concentrations during each of the experimental phases
Fatty acids (%) Treatment Baseline Endpoint Change (Difference)
C20:5n-3 Eicosapentaenoic acid (EPA) HPL Krill oil 0.79 ± 0.07 2.05 ± 0.12a 1.26 ± 0.11a
LPL krill oil 0.76 ± 0.06 1.98 ± 0.11a 1.23 ± 0.13a
Control 0.88 ± 0.08 0.76 ± 0.10 −0.12 ± 0.07
C22:5n-3 Docosapentaenoic acid (DPA) HPL Krill oil 0.63 ± 0.07 0.78 ± 0.06ab 0.15 ± 0.05a
LPL krill oil 0.76 ± 0.04 0.98 ± 0.05a 0.22 ± 0.04a
Control 0.65 ± 0.06 0.61 ± 0.04 −0.04 ± 0.05
C22:6n-3 Docosahexaenoic acid (DHA) HPL Krill oil 2.97 ± 0.13 3.99 ± 0.19ab 1.01 ± 0.15a
LPL krill oil 3.06 ± 0.12 4.35 ± 0.22a 1.29 ± 0.13a
Control 3.15 ± 0.14 2.90 ± 0.13 −0.25 ± 0.16
Total SFA HPL Krill oil 43.36 ± 0.44 42.80 ± 0.35b −0.57 ± 0.45b
LPL krill oil 44.99 ± 0.66 41.83 ± 0.34 −3.16 ± 0.72a
Control 41.69 ± 1.11 42.49 ± 0.37 0.79 ± 1.12
Total MUFA HPL Krill oil 17.58 ± 0.68 16.44 ± 0.57 −1.13 ± 0.68b
LPL krill oil 12.73 ± 1.31 15.65 ± 0.47a 2.92 ± 1.30
Control 17.63 ± 0.70 16.96 ± 0.51 −0.67 ± 0.68
Total PUFA HPL Krill oil 39.06 ± 0.54 40.76 ± 0.44b 1.70 ± 0.55
LPL krill oil 42.27 ± 0.77 42.52 ± 0.47a 0.25 ± 0.77
Control 40.68 ± 0.94 40.56 ± 0.46 −0.12 ± 1.12
Total n-6 PUFA HPL Krill oil 34.04 ± 0.54 33.36 ± 0.45a −0.68 ± 0.43b
LPL krill oil 37.09 ± 0.77 34.61 ± 0.59 −2.48 ± 0.67a
Control 35.40 ± 0.86 35.70 ± 0.42 0.30 ± 0.96
Total n-3 PUFA HPL Krill oil 5.02 ± 0.16 7.40 ± 0.28a 2.38 ± 0.24a
LPL krill oil 5.19 ± 0.16 7.91 ± 0.32a 2.72 ± 0.27a
Control 5.28 ± 0.21 4.86 ± 0.15 −0.42 ± 0.20
n-6:n-3 HPL Krill oil 6.93 ± 0.27 4.69 ± 0.26a −2.25 ± 0.23a
LPL krill oil 7.29 ± 0.29 4.58 ± 0.27a −2.72 ± 0.19a
Control 6.87 ± 0.28 7.46 ± 0.23 0.59 ± 0.17
EPA + DHA HPL Krill oil 3.76 ± 0.15 6.04 ± 0.28a 2.27 ± 0.22a
LPL krill oil 3.82 ± 0.14 6.33 ± 0.30a 2.51 ± 0.23a
Control 4.03 ± 0.19 3.66 ± 0.13 −0.37 ± 0.18
Values are expressed as Mean ± SEM. n = 20. a and b denote significance compared with control or LPL krill oil interventions respectively
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are capable of modifying the surface structure of
ingested fats which help pancreatic lipases to cleave long
chain fatty acids [19]. In addition, PLs help in mixed
micelle formation and enhance lipid absorption. In
humans, dietary PLs are hydrolysed to lysoPC and free
fatty acid (FFA) which are then absorbed through the
enterocytes or after binding to albumin, a process which
increases the delivery of PUFAs to tissues [20, 21]. Stud-
ies in animals suggest that up to 20 % of the may also be
absorbed intact, without being first cleaved by PLA2
[22–25]. Studies have also shown that lysoPC could
preferentially be a vehicle to deliver DHA to the brain
[26, 27]. DHA is transported in plasma as either non es-
terified or lysoPC forms. Non esterified form of DHA
gets delivered to platelets, whereas lysoPC form is
delivered to RBC [28]. In both humans and mice, there
was a proportional association between plasma and diet-
ary EPA, whereas saturable incorporation of DHA into
plasma lipids was found [29, 30]. Mechanisms by which
the fatty acids are taken by the cells involves carrier me-
diated as well as passive transmembrane translocation
[31, 32]. Hence, concentration of PL might have influ-
enced the incorporation of n-3 PUFA into the RBC in
the current study.
Intake of <300 mg/d of DHA by humans have been pre-
viously shown not to change the RBC concentrations of
DHA [33, 34]. Dosage of DHA with high or low PL in the
current study is around 200 mg/d which is comparable to
dosage of these previous reports. In addition, Ramprasath
et al. have previously shown that krill oil is more efficient
Table 3 RBC fatty acids concentrations during each of the experimental phases
Fatty acids (%) Treatment Baseline Endpoint Change (difference)
C20:5n-3 Eicosapentaenoic acid (EPA) HPL Krill oil 0.82 ± 0.05 1.51 ± 0.09ab 0.69 ± 0.06ab
LPL krill oil 0.66 ± 0.04 1.09 ± 0.06a 0.43 ± 0.06a
Control 0.83 ± 0.05 0.73 ± 0.05 −0.09 ± 0.03
C22:5n-3 Docosapentaenoic acid (DPA) HPL Krill oil 2.26 ± 0.06 2.42 ± 0.05b 0.16 ± 0.04b
LPL krill oil 1.68 ± 0.12 1.65 ± 0.13a −0.03 ± 0.14
Control 2.46 ± 0.15 2.53 ± 0.20 0.07 ± 0.24
C22:6n-3 Docosahexaenoic acid (DHA) HPL Krill oil 4.21 ± 0.18 4.55 ± 0.17ab 0.34 ± 0.09a
LPL krill oil 3.26 ± 0.21 3.14 ± 0.21 −0.12 ± 0.27
Control 3.70 ± 0.39 3.71 ± 0.31 0.02 ± 0.41
Total SFA HPL Krill oil 43.71 ± 0.39 43.25 ± 0.41b −0.45 ± 0.43b
LPL krill oil 46.87 ± 0.81 48.98 ± 0.73a 2.11 ± 0.95a
Control 44.03 ± 0.40 43.71 ± 0.36 −0.32 ± 0.43
Total MUFA HPL Krill oil 18.11 ± 0.27 18.55 ± 0.52b 0.44 ± 0.49
LPL krill oil 17.05 ± 0.26 17.25 ± 0.26a 0.20 ± 0.27
Control 18.48 ± 0.33 18.30 ± 0.29 −0.18 ± 0.28
Total PUFA HPL Krill oil 38.18 ± 0.54 38.20 ± 0.46b 0.01 ± 0.43b
LPL krill oil 36.09 ± 0.81 33.77 ± 0.81a −2.31 ± 0.87a
Control 37.49 ± 0.53 37.99 ± 0.52 0.50 ± 0.61
Total n-6 PUFA HPL Krill oil 30.55 ± 0.46 29.38 ± 0.44ab −1.17 ± 0.36a
LPL krill oil 30.20 ± 0.58 27.59 ± 0.54a −2.61 ± 0.50a
Control 30.18 ± 0.49 30.69 ± 0.43 0.51 ± 0.52
Total n-3 PUFA HPL Krill oil 7.63 ± 0.22 8.81 ± 0.25ab 1.18 ± 0.15ab
LPL krill oil 5.88 ± 0.31 6.18 ± 0.36a 0.30 ± 0.40
Control 7.31 ± 0.38 7.30 ± 0.23 −0.01 ± 0.29
n-6:n-3 HPL Krill oil 4.08 ± 0.14 3.41 ± 0.14ab −0.67 ± 0.07a
LPL krill oil 5.36 ± 0.25 4.73 ± 0.27 −0.64 ± 0.24
Control 4.51 ± 0.41 4.29 ± 0.15 −0.22 ± 0.32
EPA + DHA HPL Krill oil 5.03 ± 0.21 6.06 ± 0.24ab 1.03 ± 0.11ab
LPL krill oil 3.92 ± 0.23 4.23 ± 0.26 0.31 ± 0.28
Control 4.53 ± 0.40 4.45 ± 0.32 −0.08 ± 0.42
Values are expressed as Mean ± SEM. n = 20. a and b denote significance compared with control or LPL krill oil interventions respectively
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than fish oil in increasing the EPA and DHA levels in
plasma as well as RBC [8]. Similarly, others [6, 7, 11] have
also reported similar findings of higher efficiency with krill
oil compared to fish oil in raising circulating n-3 PUFA
levels. Hence, PL-bound EPA and DHA from krill oil
might be absorbed more efficiently than TG- or EE-bound
EPA and DHA from fish oil. Based on the findings of the
current study, along with previous studies, it appears that
PL may play a vital role in incorporation of EPA and DHA
into the RBC. However, understanding better the exact
mechanism is of importance.
Consumption of EPA and DHA is well established to
decrease levels of plasma TG, however, it is also known
to elevate levels of LDL-C and TC [35]. Both LPL and
HPL krill oil intakes elevated total and LDL cholesterol
concentrations. An important parameter used as a risk
factor for CVD is the ratio of TC/HDL-C. This ratio did
not change in the current study, suggesting that TC and
LDL-C increase might not be detrimental. These results
support findings from our previous study which demon-
strated an incremental increase [8], as well as other
studies showing no change [6, 7, 36], in plasma concen-
trations of total and LDL cholesterol in normolipidemic
participants after krill oil supplementation. Both LPL
and HPL krill oils were well tolerated by the participants
and caused no adverse effects which shows the safety
nature of krill oil.
The current study involved a healthy population which
allowed studying the bioavailability of krill oil with differ-
ent amounts of PL on the levels of omega-3 PUFA in the
plasma as well as RBC; thus we could expect more signifi-
cant health benefits when consumed by individuals with
metabolic syndrome or increased risk for CVD. High
compliance by the participants to the study protocol in-
cluding the intake of supplements as well as restrictions
with fish, sea foods and supplements further added more
robustness to the results. A crossover design helps to
eliminate any variances due to genetic background of
participants.
Although the study was a placebo controlled cross over
study, the design was a semi randomised where the LPL
phase was added at the end of the trial and not randomised.
Same dose of n-3 PUFA/day was administered to the
participants with two levels of doses of PL which is actually
strength of the study. However, having only 3 capsules for
the LPL phase, compared to 6 capsules for the HPL and




Healthy males and non-pregnant females (n = 24; 12
males and 12 females) ages 18–49 years were recruited
by advertisement at the Richardson Centre for Func-
tional Foods and Nutraceuticals on the University of
Manitoba campus. Participants were excluded if they
have any chronic disease or admitted an allergy to fish
or sea foods, or reported consuming supplements in-
cluding n-3 PUFA in the past 6 months or consuming
more than one fish serving per month during the month
prior to the start of the study. Participants were included
if they were nonsmokers; serum TG levels <200 mg/dL;
total cholesterol <240 mg/dL; LDL-cholesterol <160 mg/
dL; BMI < 28, not consuming more than one alcoholic
Table 4 Serum lipid concentrations during the study
Parameters (mMol/L) Treatment Baseline Endpoint Change (Difference)
TG HPL Krill oil 98.02 ± 11.76 94.90 ± 9.25b −3.12 ± 5.50
LPL krill oil 106.2 ± 9.62 101.21 ± 10.41 −4.99 ± 4.74
Control 99.91 ± 10.02 101.51 ± 10.93 1.60 ± 4.78
HDL HPL Krill oil 54.52 ± 3.14 59.36 ± 3.25 4.84 ± 1.75
LPL krill oil 55.48 ± 3.33 57.81 ± 3.76 2.33 ± 1.91
Control 54.71 ± 3.02 56.65 ± 2.90 1.94 ± 1.12
LDL HPL Krill oil 94.28 ± 5.47 101.52 ± 7.00a 7.25 ± 3.67a
LPL krill oil 96.93 ± 7.25 100.32 ± 8.27a 3.40 ± 3.35
Control 93.89 ± 5.07 92.30 ± 5.70 −1.60 ± 2.79
TC HPL Krill oil 168.02 ± 6.26 179.61 ± 7.65a 11.59 ± 4.19a
LPL krill oil 173.62 ± 7.06 177.68 ± 9.18 4.06 ± 4.76
Control 169.56 ± 5.53 169.56 ± 6.06 0.00 ± 3.62
TC/HDL HPL Krill oil 3.28 ± 0.23 3.22 ± 0.26 1.50 ± 0.42
LPL krill oil 3.41 ± 0.31 3.34 ± 0.30 1.93 ± 0.58
Control 3.32 ± 0.22 3.21 ± 0.23 1.96 ± 0.74
Values are expressed as Mean ± SEM. n = 20. a and b denote significance compared with control and LPL respectively. TG- triglycerides, HDL high density
lipoprotein, LDL low density lipoprotein, TC total cholesterol
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drink/day and not taking any medications that would
interfere with lipid metabolism or to control blood lipids
or treat hypertension.
Ethics, consent and permissions
The protocol of the study was reviewed and approved by
the Human Ethical Review Committee of the University
of Manitoba (reference #B2011:014). All participants
were explained the study protocol and written consent
was obtained to participate in the study along with con-
sent for publication of the data.
Study design and intervention
A double blinded, randomized, placebo-controlled, cross-
over trial with 24 healthy participants was completed [8].
The completed study was comprised of treatments includ-
ing identical looking capsules consisting of krill oil or an
oil with high fish oil content each providing 600 mg of n-3
PUFA or a placebo, corn oil. Duration of each treatment
phase was 4 weeks separated by washout phases of
8 weeks.
At the end of the study, participants were invited to con-
tinue the study for another single blind non-randomized
phase for 12 weeks (8 washout weeks followed by 4 treat-
ment weeks). Participants, whom continued to the fourth
phase (n = 20; 11 males and 9 females), (Baseline BMI for
14 participants was <25 and BMI for 6 participants were
between 25 and 28) received three capsules per day consist-
ing of LPL krill oil providing 600 mg of n-3 PUFA (for
comparison of the oils intake and composition see Tables 5
and 6, respectively). LPL was HP K•REAL™ and HPL was
K•REAL™ pure krill oil, both by Enzymotec Ltd. Data
obtained with LPL krill phase were compared with those
from control and HPL krill oil phases. As the fish oil phase
was not needed for the current objective, data from the fish
oil phase were not used in the current investigation. All the
rest of the human and laboratory experimental methods
used were same as performed during the first three phases
[8], as follows.
Anthropometric measurements
Anthropometric and blood pressure measurements as
well as physical examinations were performed at baseline
and endpoint of each treatment following standard pro-
cedures [37].
Plasma and RBC fatty acid analyses
Fasting blood samples were collected at baseline and end-
point of each phase. Samples were centrifuged at 3000 rpm
for 20 min followed by separation of plasma and RBC and
aliquots were stored in −80 ° C until analysis.
Plasma and RBC total lipids were extracted using the
Folch method [38] which involved chloroform-methanol
(2:1, v/v) containing 0 · 01 % BHT (Sigma-Aldrich, Oakville,
ON, Canada) and heptadecanoic acid as an internal
Table 5 Daily amounts of EPA, DHA, n-3 and n-6 PUFA in the
supplements of the various study groups
Fatty acid (mg/day) Corn oil HPL Krill oil LPL Krill oil
EPA 0 337 320
DHA 0 188 207
total n-3 PUFA 30 603 608
total n-6 PUFA 1437 60 34
Table 6 Fatty acid composition of HPL krill oil, LPL krill oil and
corn oil used in the study
Fatty acid (% of total fatty acids) HPL Krill oil LPL Krill oil Corn oil
C12 (Lauric) 0.27 0 0.13
C14 (Myristic) 11.82 2.33 0.00
C14:1 (Myristoleic) 0.16 0 0.00
C15 (Pentadecanoic) 0.47 0.18 0.00
C16 (Palmitic) 22.11 12.56 15.01
C16:1 (Palmitoleic) 6.09 2.19 0.00
C17 (Margaric) 2.02 0.17 0.00
C18 (Stearic) 1.39 2.39 3.31
C18:1n9 (Oleic) 13.28 7.89 1.08
C18:1n7 (Vaccenic) 7.56 4.30 0.00
C18:2n6 (Linoleic) 2.06 1.57 77.57
C18:3n6 (gamma-Linolenic) 0.00 0.25 0.00
C18:3n3 (alpha-Linolenic) 0.93 0.96 1.61
C18:4n3 (Moroctic) 2.70 1.78 0.00
C20 (Arachidic) 0.00 0.25 0.57
C20:1n9 (Eicosenoic) 0.80 1.01 0.44
C20:2n6 (Eicosadienoic) 0.41 0.20 0.00
C20:4n6 (Arachidonic) 0.40 1.40 0.00
C20:4n3 (Eicosatetraenoic) 0.26 1.1 0.00
C20:5n3 (Eicosapentaenoic) 16.44 31.92 0.00
C21:5n3 (Docosapentaenoic) 0 1.14 0
C22 (Behenic) 0.00 0 0.27
C22:1n11 (Cetoleic) 0 0.82 0
C22:1n9 (Euricic) 0.56 0.72 0.00
C22:2n9 (Docosadienoic) 0.43 0 0.00
C22:5n6 (Docosapentaenoic) 0 0.42 0
C22:5n3 (Docosapentaenoic) 0.38 3.07 0.00
C22:6n3 (Docosahexaenoic) 9.48 20.53 0.00
C24:1n9 (Nervonic) 0.00 0.86 0.00
Total n-3 PUFA 30.18 60.49 1.61
Total n-6 PUFA 2.86 3.84 77.57
Total n-9 PUFA 15.07 10.48 1.52
Total PUFA 33.47 64.33 79.18
Total MUFA 28.46 17.80 1.52
Total SFA 38.07 17.88 19.30
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standard (Sigma-Aldrich, Oakville, ON, Canada). Extracted
fatty acids were methylated with methanolic HCl. Fatty acid
methyl esters were separated on a Supelcowax 10 column
(30 m X 0 · 25 mm with 0 · 25 mm film thickness; Supelco,
Bellefonte, PA, USA) using a gas chromatograph equipped
with a flame ionisation detector (Bruker 430). Individual
fatty acids were identified by comparison with known stan-
dards (NuChek Prep, Inc., Elysian, MN, USA). Individual
fatty acids were calculated according to the peak area rela-
tive to the total area and expressed as the percentage of
total fatty acids [8].
Serum lipid profiles including total and HDL-cholesterol
and triglyceride levels were measured using a Vitros 350
Autoanalyser (Orthoclinical diagnostics). LDL-cholesterol
levels were calculated using Friedewald equation [39].
Complete blood counts were also determined using a
Beckmann coulter LH780 at baseline and at endpoint of
each treatment phase.
Statistical analysis
Control, HPL and LPL krill oil treatment phases were
compared to each other. Differences between LPL and
HPL krill oil and placebo treatments were analyzed for
each dependent measure. Normal distribution of the
variables was tested by Shapiro Wilkes test. Variables
were analyzed by two-tailed paired student’s t-test for
normally distributed variables or by Wilcoxon’s signed
rank test for non-parametric variables. Values were
expressed as mean ± SEM and p values < 0.05 were con-
sidered significant. Safety data were examined descrip-
tively for each arm and compared across treatments.
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